STOCK TITAN

Immunovant (IMVT) CFO exercises options, sells 10,000 shares at ~$38 average

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Immunovant, Inc. Chief Financial Officer Tiago Girao reported an exercise-and-sell transaction in company stock. He exercised stock options to acquire 10,000 shares of Common Stock at a price of $15.90 per share and then sold 10,000 shares in open-market transactions at a weighted average price of $38.46 per share. After these transactions, he directly holds 247,596 Common Shares. The filing notes that the sale was executed in multiple trades between $38.00 and $38.90 per share.

Positive

  • None.

Negative

  • None.
Insider Girao Tiago
Role Chief Financial Officer
Sold 10,000 shs ($385K)
Type Security Shares Price Value
Exercise Stock Option (right to buy) 10,000 $0.00 --
Exercise Common Stock 10,000 $15.90 $159K
Sale Common Stock 10,000 $38.46 $385K
Holdings After Transaction: Stock Option (right to buy) — 283,505 shares (Direct, null); Common Stock — 257,596 shares (Direct, null)
Footnotes (1)
  1. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.00 - $38.90 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Award of stock options to purchase Common Shares with a grant date of May 1, 2025. The shares underlying the option vest as to 25% on April 21, 2026, with the remainder vesting in 12 successive substantially equal quarterly installments over three years thereafter, subject to the Reporting Person's continued service to the Issuer as of such date.
Shares sold 10,000 shares Common Stock sold in open-market transactions
Weighted average sale price $38.46 per share Common Stock sale on 2026-06-26
Sale price range $38.00–$38.90 per share Multiple transactions, weighted average disclosed
Options exercised 10,000 shares Stock Option (right to buy) converted into Common Stock
Exercise price $15.90 per share Conversion or exercise price for stock options
Shares held after transaction 247,596 shares Direct Common Stock ownership following sale
Option grant date May 1, 2025 Grant date for stock option award described in footnote
Initial vesting date April 21, 2026 25% of option award vests on this date
weighted average price financial
"The price reported is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
stock options financial
"Award of stock options to purchase Common Shares with a grant date of May 1, 2025."
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
grant date financial
"Award of stock options to purchase Common Shares with a grant date of May 1, 2025."
The grant date is the day a company formally gives an employee or contractor the right to receive stock-based compensation, such as stock options or restricted shares. It matters to investors because it fixes key terms—like the price, the start of the ownership clock, and when the award will affect the company’s financial statements and share count—so it can influence dilution, reported expenses, and potential future selling pressure.
vest financial
"The shares underlying the option vest as to 25% on April 21, 2026, with the remainder vesting in 12 successive substantially equal quarterly installments over three years thereafter"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
Stock Option (right to buy) financial
"Stock Option (right to buy) reported as a derivative security with underlying Common Stock"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Girao Tiago

(Last)(First)(Middle)
C/O IMMUNOVANT, INC.
1000 PARK FORTY PLAZA, SUITE 210

(Street)
DURHAM NORTH CAROLINA 27713

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Immunovant, Inc. [ IMVT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Financial Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/26/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/26/2026M10,000A$15.9257,596D
Common Stock06/26/2026S10,000D$38.46(1)247,596D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$15.906/26/2026M10,000 (2)05/01/2035Common Stock10,000$0283,505D
Explanation of Responses:
1. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.00 - $38.90 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
2. Award of stock options to purchase Common Shares with a grant date of May 1, 2025. The shares underlying the option vest as to 25% on April 21, 2026, with the remainder vesting in 12 successive substantially equal quarterly installments over three years thereafter, subject to the Reporting Person's continued service to the Issuer as of such date.
Remarks:
/s/ Tiago Girao06/26/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Immunovant (IMVT) report for Tiago Girao?

Immunovant reported that CFO Tiago Girao exercised stock options for 10,000 Common Shares and sold 10,000 shares in the open market. The exercise price was $15.90 per share and the weighted average sale price was $38.46 per share.

How many Immunovant (IMVT) shares did the CFO sell and at what price?

Tiago Girao sold 10,000 shares of Immunovant Common Stock in open-market transactions at a weighted average price of $38.46 per share. The trades occurred within a price range from $38.00 to $38.90 per share, according to the filing footnote.

What is Tiago Girao’s Immunovant (IMVT) shareholding after the reported Form 4?

Following the reported transactions, CFO Tiago Girao directly holds 247,596 shares of Immunovant Common Stock. This figure reflects his position after exercising 10,000 options and selling 10,000 shares, as disclosed in the non-derivative transaction table of the Form 4.

What stock options did the Immunovant (IMVT) CFO exercise in this filing?

The Form 4 shows Tiago Girao exercised stock options covering 10,000 shares of Common Stock at a conversion or exercise price of $15.90 per share. This exercise is paired with a derivative entry for a Stock Option (right to buy) linked to the same 10,000 underlying shares.

How does the Form 4 describe the price range for Immunovant (IMVT) share sales?

The filing states that the reported sale price is a weighted average, with individual trades executed between $38.00 and $38.90 per share. The footnote notes that detailed trade-level pricing information is available to the issuer, security holders, or SEC staff upon request.

What vesting terms are disclosed for the Immunovant (IMVT) CFO’s stock options?

A footnote describes an award of stock options with a grant date of May 1, 2025. Twenty-five percent of the underlying shares vest on April 21, 2026, with the remaining options vesting in 12 substantially equal quarterly installments over three years, subject to continued service.